Neurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14

Seeking Alpha2022-01-07

The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

458fd99c
2022-01-07
458fd99c
Ha
- 458fd99c:
  Ya

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1115875737?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2022-01-07 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115875737","market":"us","top_or_hot":-1,"title":"Neurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14","media":"Seeking Alpha","content":"<div>\n<p>The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a...</p>\n\n<a href=\"https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a...</p>\n\n<a href=\"https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VIGL","symbol_name":"Vigil Neuroscience, Inc.","start_time":0,"source_url":"https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14","article_id":"1115875737","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115875737","pubTimestamp":1641554290,"sourceInfo":null,"weMediaInfo":null,"summary":"The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc."},"translate_title":"神经退行性疾病生物技术守夜神经科学700万股IPO定价14美元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIGL":0.9},"content_text":"The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a price range of $15-$17.Underwriters' over-allotment is an additional 1.05M shares.Nasdaq trading will commence today on January 7, 2022.Closing date is January 11.The company is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain.Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. In November 2021, the FDA cleared Vigil's IND for VGL101 in ALSP.The company initiated its first-in-human Phase 1 trial in December, and topline data is expected in the 2H22.Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are the joint bookrunners on the deal.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":695427498,"gmtCreate":1641556079714,"gmtModify":1641556101576,"author":{"id":"3527303552443900","authorId":"3527303552443900","name":"458fd99c","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ha","listText":"Ha","text":"Ha","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/695427498","repostId":1115875737,"repostType":4,"repost":{"id":"1115875737","pubTimestamp":1641554290,"share":"https://www.laohu8.com/m/news/1115875737?lang=&edition=full","pubTime":"2022-01-07 19:18","market":"us","language":"en","title":"Neurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14","url":"https://stock-news.laohu8.com/highlight/detail?id=1115875737","media":"Seeking Alpha","summary":"The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $","content":"<html><head></head><body><ul><li>The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.</li><li>The company initially filed to offer7M shares at a price range of $15-$17.</li><li>Underwriters&#39; over-allotment is an additional 1.05M shares.</li><li>Nasdaq trading will commence today on January 7, 2022.</li><li>Closing date is January 11.</li><li>The company is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain.</li><li>Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. In November 2021, the FDA cleared Vigil&#39;s IND for VGL101 in ALSP.</li><li>The company initiated its first-in-human Phase 1 trial in December, and topline data is expected in the 2H22.</li></ul><p><img src=\"https://static.tigerbbs.com/62cadd2e0bb48ea076c2cbd4391f3105\" tg-width=\"996\" tg-height=\"482\" width=\"100%\" height=\"auto\"/></p><ul><li>Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are the joint bookrunners on the deal.</li></ul></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurodegenerative Disease Biotech Vigil Neuroscience Prices 7M-Share IPO at $14\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-07 19:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a...</p>\n\n<a href=\"https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIGL":"Vigil Neuroscience, Inc."},"source_url":"https://seekingalpha.com/news/3786110-neurodegenerative-disease-biotech-vigil-neuroscience-prices-7m-share-ipo-at-14","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115875737","content_text":"The Cambridge, MA-based Vigil Neuroscience (VIGL) haspricedits IPO of 7M shares of common stock at $14.00/share, for expected grossproceeds of $98.0M.The company initially filed to offer7M shares at a price range of $15-$17.Underwriters' over-allotment is an additional 1.05M shares.Nasdaq trading will commence today on January 7, 2022.Closing date is January 11.The company is utilizing a precision medicine approach to develop a pipeline of therapies, initially addressing genetically defined patient subpopulations, that it believes will activate and restore immune cell function within the brain.Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. In November 2021, the FDA cleared Vigil's IND for VGL101 in ALSP.The company initiated its first-in-human Phase 1 trial in December, and topline data is expected in the 2H22.Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities are the joint bookrunners on the deal.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7162246,"gmtCreate":1641556083916,"gmtModify":1641556083958,"authorId":3527303552443900,"author":{"id":3527303552443900,"authorId":3527303552443900,"name":"458fd99c","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":695427498,"type":1,"supId":0,"prevId":0,"content":"<u>Ya</u>","text":"<u>Ya</u>","html":"<u>Ya</u>"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115875737"}